FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Immunotherapy
- Sub-indication
- Lung Cancer
Related signal: Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer